Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Clinical trial NCT04811092 · TERMINATED

Trial details

NCT number: NCT04811092
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Pulmonary Arterial Hypertension

Start date: 2022-03-18
Primary completion: 2025-04-03
Enrollment: 321

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.